1. Home
  2. ADAP vs WETO Comparison

ADAP vs WETO Comparison

Compare ADAP & WETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADAP
  • WETO
  • Stock Information
  • Founded
  • ADAP 2008
  • WETO 2019
  • Country
  • ADAP United Kingdom
  • WETO China
  • Employees
  • ADAP N/A
  • WETO N/A
  • Industry
  • ADAP Biotechnology: Pharmaceutical Preparations
  • WETO
  • Sector
  • ADAP Health Care
  • WETO
  • Exchange
  • ADAP Nasdaq
  • WETO NYSE
  • Market Cap
  • ADAP 75.5M
  • WETO 88.0M
  • IPO Year
  • ADAP 2015
  • WETO 2025
  • Fundamental
  • Price
  • ADAP $0.29
  • WETO $2.90
  • Analyst Decision
  • ADAP Buy
  • WETO
  • Analyst Count
  • ADAP 6
  • WETO 0
  • Target Price
  • ADAP $1.52
  • WETO N/A
  • AVG Volume (30 Days)
  • ADAP 1.6M
  • WETO 1.4M
  • Earning Date
  • ADAP 05-13-2025
  • WETO 01-01-0001
  • Dividend Yield
  • ADAP N/A
  • WETO N/A
  • EPS Growth
  • ADAP N/A
  • WETO N/A
  • EPS
  • ADAP N/A
  • WETO N/A
  • Revenue
  • ADAP $179,639,000.00
  • WETO $5,350,773.00
  • Revenue This Year
  • ADAP N/A
  • WETO N/A
  • Revenue Next Year
  • ADAP $52.49
  • WETO N/A
  • P/E Ratio
  • ADAP N/A
  • WETO N/A
  • Revenue Growth
  • ADAP 878.53
  • WETO N/A
  • 52 Week Low
  • ADAP $0.20
  • WETO $1.50
  • 52 Week High
  • ADAP $1.48
  • WETO $4.30
  • Technical
  • Relative Strength Index (RSI)
  • ADAP 53.94
  • WETO N/A
  • Support Level
  • ADAP $0.26
  • WETO N/A
  • Resistance Level
  • ADAP $0.30
  • WETO N/A
  • Average True Range (ATR)
  • ADAP 0.03
  • WETO 0.00
  • MACD
  • ADAP 0.00
  • WETO 0.00
  • Stochastic Oscillator
  • ADAP 58.12
  • WETO 0.00

About ADAP Adaptimmune Therapeutics plc

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.

About WETO WEBUS INTERNATIONAL LIMITED

Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.

Share on Social Networks: